Silverback Therapeutics Inc at H C Wainwright Bioconnect Conference (Virtual) Transcript
Hello, and welcome, everyone. Thank you for joining the H.C. Wainwright BioConnect 2022 Conference. My name is Steve Verse. I'm an equity research associate here at H.C. Wainwright. Now I'd like to introduce our next presenters, Laura Shawver, CEO of Silverback Therapeutics; and Valerie Odegard, President and Chief Scientific Officer.
Silverback is focused on its proprietary ImmunoTAC platform to develop a new generation of systemically-delivered tissue-targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases. So now I'll turn it over to Laura.
Thank you, Stephen. Good morning, everyone. Thank you to H.C. Wainwright for the opportunity to present the Silverback company overview. And thank you to the listeners for your interest. Before I start, on Slide 2 is our disclosure about forward-looking statements in this presentation, including statements regarding our business in the expected timing and impact of future events.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |